List of Excipients in Branded Drug PIOGLITAZONE AND METFORMIN

« Back to Dashboard

Generic Drugs Containing PIOGLITAZONE AND METFORMIN

Company	Ingredient	NDC	Excipient
Sandoz Inc	pioglitazone and metformin	0781-5626	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	pioglitazone and metformin	0781-5626	CROSCARMELLOSE SODIUM
Sandoz Inc	pioglitazone and metformin	0781-5626	HYDROXYPROPYL CELLULOSE
Sandoz Inc	pioglitazone and metformin	0781-5626	HYPROMELLOSE 2910
Sandoz Inc	pioglitazone and metformin	0781-5626	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PIOGLITAZONE AND METFORMIN?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSE 2910
2	MAGNESIUM STEARATE

Pioglitazone and Metformin Excipient Strategy and Commercial Opportunities

Last updated: October 24, 2026

The commercial opportunity for pioglitazone/metformin is concentrated in low-cost generic fixed-dose combinations, modified-release products, and differentiated formulations for patients who need glucose lowering with reduced pill burden. The main formulation challenge is combining a low-dose, poorly soluble thiazolidinedione with high-dose, highly water-soluble metformin hydrochloride while controlling tablet size, mechanical strength, dissolution, and gastrointestinal tolerability.

What is the commercial role of pioglitazone/metformin?

Pioglitazone/metformin combines two oral antihyperglycemic agents with different mechanisms:

• Metformin reduces hepatic glucose production and improves insulin sensitivity.
• Pioglitazone activates PPAR-gamma and improves insulin sensitivity in adipose tissue, skeletal muscle, and the liver.

The combination is used for adults with type 2 diabetes when metformin alone is inadequate or when patients are already receiving both ingredients separately. Pioglitazone is associated with weight gain, edema, heart-failure risk, bone-fracture risk, and a bladder-cancer warning. Metformin carries a lactic-acidosis warning, particularly in patients with significant renal impairment. These safety issues limit the addressable market compared with newer combinations involving SGLT2 inhibitors or GLP-1 receptor agonists (FDA, 2023a; FDA, 2023b).

The primary commercial value proposition is operational rather than novel pharmacology:

1. Fewer tablets.
2. Lower acquisition cost than newer branded combinations.
3. Simplified prescribing for patients already stabilized on both ingredients.
4. Potential adherence improvement.
5. Access in price-sensitive markets where pioglitazone remains widely used.

What dosage forms and strengths are commercially relevant?

Immediate-release and extended-release tablets are the principal dosage forms. Historical branded products included Actoplus Met and Actoplus Met XR, while multiple generic manufacturers have supplied equivalent or therapeutically interchangeable products.

Product concept	Typical strength profile	Formulation objective	Commercial position
Immediate-release fixed-dose tablet	Pioglitazone 15 mg with metformin 500, 850, or 1,000 mg	Match separate immediate-release dosing	Lowest-cost generic opportunity
Extended-release fixed-dose tablet	Pioglitazone 15 or 30 mg with metformin extended release, commonly 1,000 mg	Reduce dosing frequency and metformin-related gastrointestinal effects	Differentiated generic or specialty product
Bilayer tablet	Low-dose pioglitazone layer plus metformin layer	Separate incompatible processing or dissolution requirements	Higher technical barrier
Multiparticulate capsule	Metformin matrix or pellets plus pioglitazone granules	Flexible release control and dose combinations	Niche opportunity with higher development cost
Abuse-resistant or swallowability-focused tablet	Modified geometry, coating, or dispersion	Improve handling and patient acceptability	Limited direct value for this combination

Exact marketed strengths and inactive ingredients vary by manufacturer and regulatory jurisdiction. The FDA-approved labeling for Actoplus Met identifies immediate-release combination strengths that include 15/500 mg, 15/850 mg, and 15/1,000 mg; extended-release labeling includes 15/1,000 mg and 30/1,000 mg presentations (FDA, 2016a; FDA, 2016b).

What excipients are suitable for pioglitazone/metformin tablets?

An excipient system should address five technical problems: metformin’s high dose, the different solubility profiles of the two active ingredients, tablet mass, compression performance, and dissolution control.

Fillers and compression aids

Microcrystalline cellulose is a strong first-line filler and dry-binder for immediate-release tablets. It improves compactibility and can compensate for metformin’s poor tableting behavior at high drug loading.

Mannitol is useful when mouthfeel, low hygroscopicity, or a cooling sensation is commercially relevant. It generally costs more than standard lactose-based systems and may not provide sufficient compactibility alone.

Dibasic calcium phosphate can improve flow and compression but may create a denser, heavier tablet. Its use requires compatibility and dissolution screening with the selected manufacturing process.

Lactose should be evaluated carefully. Metformin contains primary and secondary amine functionality, creating a potential Maillard-reaction risk with reducing sugars under certain moisture and temperature conditions. Lactose-based systems may remain viable after compatibility testing, but they are less attractive when long-term color stability and impurity control are critical.

Binders

Povidone and copovidone are established binders for wet granulation and dry granulation. Povidone can improve granule strength but may increase moisture sensitivity and slow drug release if used at excessive levels.

Hydroxypropyl cellulose is another option for dry or wet granulation. It can improve compactibility without the same level of viscosity increase associated with some higher-viscosity polymers.

For direct compression, a high-functionality microcrystalline cellulose or silicified microcrystalline cellulose can reduce process complexity and avoid aqueous exposure.

Disintegrants

Croscarmellose sodium, sodium starch glycolate, and crospovidone are conventional choices.

Crospovidone often supports rapid water uptake and tablet breakup without excessive gelling. Croscarmellose sodium provides strong swelling and is widely used in immediate-release products. Sodium starch glycolate can be effective but may produce variable performance if granule porosity and lubricant levels are not controlled.

The disintegrant must be balanced against metformin’s high solubility. Excessive disintegration is not automatically beneficial if it increases tablet friability or causes inconsistent dissolution across strengths.

Lubricants and glidants

Magnesium stearate is the standard lubricant, but over-lubrication can reduce tablet tensile strength and delay wetting. This risk is material in high-dose metformin tablets because prolonged blending can create a hydrophobic particle coating.

Sodium stearyl fumarate is an alternative lubricant when dissolution sensitivity or over-lubrication is a concern. Colloidal silicon dioxide can improve flow, especially in direct-compression blends, but may increase dusting and require careful containment.

Film-coating systems

Hypromellose-based aqueous film coatings are appropriate for immediate-release products when the objective is identification, taste masking, moisture protection, and improved mechanical durability.

Polyvinyl alcohol-based coatings can provide a thinner, robust coating with good appearance. Polyethylene glycol plasticizers can improve flexibility but may affect moisture transmission.

For extended-release tablets, the coating or matrix polymer must be selected based on the desired metformin release profile. Hypromellose matrix systems are common, but high-dose metformin may require multilayer compression or a high-polymer matrix to prevent rapid release.

What formulation strategy best controls dissolution?

The most practical development sequence is to begin with an immediate-release dry-granulated or direct-compression tablet, then assess whether a differentiated extended-release product justifies the additional development cost.

Immediate-release strategy

A feasible immediate-release platform may use:

• Metformin hydrochloride as the primary high-load component.
• Micronized or controlled-particle-size pioglitazone hydrochloride.
• Microcrystalline cellulose or silicified microcrystalline cellulose.
• Crospovidone or croscarmellose sodium.
• Povidone or copovidone if granulation is needed.
• Magnesium stearate or sodium stearyl fumarate.
• Colloidal silicon dioxide for flow.
• Hypromellose film coating.

Dry granulation is commercially attractive because it reduces water exposure, shortens processing time, and can support continuous or high-throughput manufacturing. Roller compaction must be controlled because excessive densification can slow metformin dissolution and create tablet capping after compression.

Extended-release strategy

Extended-release development is more technically demanding because metformin is present at a much higher mass than pioglitazone. A single matrix tablet may require:

• A hydrophilic polymer such as hypromellose.
• A release-modifying polymer blend.
• A carefully controlled tablet porosity.
• A protective film coat.
• Strong in vitro-in vivo correlation work.

A bilayer architecture can separate the immediate or controlled release of pioglitazone from metformin’s extended-release matrix. It also creates a stronger manufacturing and intellectual-property position, but requires bilayer compression equipment, tighter weight control, and more extensive robustness testing.

What excipient risks should manufacturers evaluate?

Excipient selection should be driven by stability, dissolution, and process risk rather than by ingredient cost alone.

Risk	Likely cause	Development response
Tablet capping or lamination	High drug load, insufficient binder, excessive compression speed	Optimize granulation, dwell time, and compression force
Slow metformin dissolution	Over-lubrication or excessive matrix density	Reduce lubricant exposure and adjust porosity
Pioglitazone content-uniformity failure	Low dose relative to metformin mass	Use ordered mixing, controlled particle size, or pregranulation
Discoloration	Moisture, heat, or reducing-sugar interaction	Use nonreducing fillers where justified and control water activity
Variable assay	Segregation during blending or transfer	Match particle-size distributions and reduce transfer distances
High friability	Weak compactibility or insufficient binder	Use silicified cellulose, copovidone, or optimized granulation
Gastrointestinal intolerance	Rapid metformin release or high local concentration	Evaluate extended release and food-effect performance
Stability failure	Moisture ingress or polymer interaction	Use moisture-barrier packaging and accelerated-stability testing

What FDA regulatory pathway applies to generic pioglitazone/metformin?

A conventional generic product generally proceeds through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, together with adequate chemistry, manufacturing, and controls data.

For an immediate-release product, the principal technical burden is usually:

• Strength and composition matching.
• Assay and content uniformity.
• Comparative dissolution.
• Bioequivalence.
• Stability.
• Manufacturing controls for high-dose metformin.

An extended-release or materially reformulated product may require more complex comparative pharmacokinetic studies and additional justification. A 505(b)(2) application may be relevant where the formulation differs materially from an approved reference product and the sponsor seeks to rely partly on existing findings rather than pursue a fully independent new drug program (FDA, 2022).

What is the Orange Book and exclusivity status of pioglitazone/metformin?

Pioglitazone and metformin are small-molecule drugs, so biosimilar regulation does not apply. The relevant competitive pathways are generic abbreviated applications, authorized generics, and reformulated products.

The core composition and product patents associated with branded pioglitazone and pioglitazone/metformin products have largely expired. Pioglitazone’s principal U.S. compound patent expired in the early 2010s, while branded combination-product exclusivity has also elapsed. The commercial opportunity is therefore not based on blocking generic entry through basic active-ingredient patents.

Current Orange Book analysis should focus on:

• Whether any listed patents remain for a specific reference product.
• Whether any formulation or method-of-use patents have survived.
• Patent-certification timing under Paragraph I, II, III, or IV.
• Whether a generic applicant has made a Paragraph IV certification.
• Whether a 30-month stay was triggered by patent litigation.

The Orange Book distinguishes patents listed against a reference product from broader patent rights that may exist outside the listed-drug framework. A patent may affect litigation risk without creating a listed-drug barrier to ANDA approval (FDA, 2024).

Which companies are challenging pioglitazone/metformin exclusivity?

The market has already moved beyond the primary branded exclusivity period. Generic pharmaceutical manufacturers, including large U.S. and international suppliers, compete on manufacturing cost, supply reliability, dossier breadth, and contracting rather than on a single high-value Paragraph IV campaign.

No biosimilar challenge applies. Any current challenge would most likely involve:

• A generic immediate-release ANDA.
• A generic extended-release product.
• A regional dossier for markets outside the United States.
• A patent certification directed to a residual formulation or method-of-use claim.
• A reformulated product using a different release-control system.

Brand-linked litigation risk is materially lower than for newer diabetes products with active formulation, device, or biologic patents.

What generic entry risks exist for pioglitazone/metformin?

Generic entry risk is high for conventional immediate-release tablets because the active ingredients are old, the pharmacology is well established, and the reference product does not require a complex delivery device.

The principal barriers are commercial rather than legal:

• Low selling prices.
• Pharmacy substitution.
• Limited reimbursement differentiation.
• High metformin tablet mass.
• Manufacturing scale requirements.
• Narrow gross margins.
• Supply-chain exposure for metformin API.
• Price competition after multiple ANDA approvals.

Extended-release products have a stronger technical barrier but also require a larger investment in formulation, bioequivalence, dissolution method development, and manufacturing validation.

What commercial opportunities remain?

Low-cost fixed-dose combinations

The clearest opportunity is a dependable immediate-release product with multiple strengths, simple packaging, and broad pharmacy-channel access. Manufacturing cost, supply continuity, and low tablet weight should be prioritized over cosmetic differentiation.

Extended-release products

An extended-release combination may attract patients who experience gastrointestinal intolerance with immediate-release metformin or who prefer once-daily dosing. The product must demonstrate a meaningful pharmacokinetic or adherence advantage because the underlying active ingredients are generic.

Emerging-market supply

Pioglitazone remains relevant in many markets where treatment cost is a major constraint. Opportunities exist for:

• Blister-pack products.
• Regional contract manufacturing.
• Government and tender supply.
• Multiple strength portfolios.
• Heat- and moisture-resistant packaging.
• Combination products aligned with local treatment guidelines.

Patient-centered tablet design

The high metformin dose creates a large tablet. Commercial differentiation may come from caplet geometry, film coating, score lines where permitted, swallowability testing, and packaging that supports adherence.

Co-packaged therapy

Where fixed-dose approval is difficult or clinical titration is important, a co-packaged pioglitazone tablet and metformin tablet may provide a lower-risk commercial bridge. This approach has less formulation novelty but permits independent dose adjustment.

How strong is the patent estate for pioglitazone/metformin?

The basic patent estate is weak for blocking generic entry because the underlying active ingredients and early branded products are mature. Potentially stronger positions can arise from:

• Extended-release matrices.
• Bilayer tablets.
• Specific dissolution profiles.
• Stabilized compositions.
• Manufacturing processes.
• Novel particle-size distributions.
• Fixed-dose combinations with additional active ingredients.

These claims must be drafted around measurable technical features and supported by comparative data. Broad claims covering pioglitazone and metformin together are vulnerable to validity and obviousness challenges because the combination has long clinical and commercial history.

What licensing deals and manufacturing partnerships are relevant?

The most credible licensing opportunities involve formulation technology, regional commercialization, or manufacturing capacity rather than rights to the active ingredients. Attractive structures include:

• Technology transfer for extended-release metformin matrices.
• Contract manufacturing of high-volume immediate-release tablets.
• Regional licenses for fixed-dose combinations.
• Supply agreements for metformin hydrochloride and pioglitazone hydrochloride.
• Co-development of bilayer or multiparticulate dosage forms.

A license has greater value when it includes validated dissolution methods, scale-up data, stability packages, and regulatory documentation. The active-ingredient rights alone are unlikely to support a high-value transaction.

Key Takeaways

• Pioglitazone/metformin is a mature small-molecule combination with high generic-entry risk.
• Immediate-release tablets offer the lowest development cost but the weakest differentiation.
• Extended-release and bilayer formulations provide stronger technical and commercial positioning.
• Microcrystalline cellulose, crospovidone or croscarmellose sodium, controlled lubrication, and nonreducing filler systems are practical starting points.
• Lactose requires compatibility assessment because metformin’s amine functionality may create discoloration or impurity risks.
• The largest formulation challenge is controlling high-dose metformin while maintaining pioglitazone uniformity and acceptable tablet size.
• No biosimilar pathway applies.
• The strongest remaining commercial opportunities are low-cost supply, extended release, emerging-market distribution, and manufacturing partnerships.
• Patent value is more likely to come from formulation and manufacturing claims than from basic composition claims.

FAQs

Is pioglitazone/metformin still commercially attractive?

Yes, but mainly as a cost-efficient generic or differentiated extended-release product. Premium pricing is difficult without a measurable adherence, tolerability, or dosing advantage.

Which excipient is best for high-dose metformin tablets?

Microcrystalline cellulose or silicified microcrystalline cellulose is a practical starting point because each supports compactibility and process robustness. The final choice depends on dissolution, tablet size, and manufacturing method.

Can lactose be used in pioglitazone/metformin tablets?

It can be evaluated, but compatibility testing is important because metformin contains amine functionality and lactose is a reducing sugar. Nonreducing fillers may provide a cleaner stability profile.

Does pioglitazone/metformin have biosimilar competition?

No. Both active ingredients are small molecules. Competition occurs through generic drug applications and reformulated products, not biosimilar applications.

What is the strongest formulation opportunity for this combination?

A once-daily extended-release or bilayer tablet with demonstrated gastrointestinal-tolerability and adherence benefits offers the strongest formulation-based differentiation, although it requires more extensive development than an immediate-release generic.

References

U.S. Food and Drug Administration. (2016a). Actoplus Met (pioglitazone hydrochloride and metformin hydrochloride) tablets: Prescribing information. FDA.

U.S. Food and Drug Administration. (2016b). Actoplus Met XR (pioglitazone hydrochloride and metformin hydrochloride extended-release) tablets: Prescribing information. FDA.

U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.

U.S. Food and Drug Administration. (2023a). Metformin hydrochloride prescribing information. FDA.

U.S. Food and Drug Administration. (2023b). Pioglitazone hydrochloride prescribing information. FDA.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.